Valued at $657.0M at its Series B, Aug 2024. Nothing has traded since.
- ·36 fund marks: filer, period, implied $/share
Membership and data by Private Market View
Valuation timeline
0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026Membership and data by Private Market View
Candid Therapeutics funding history
1 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| Aug 2024 | Early Stage VC (Series B) | $370.0M | ▮ | ▮ |
Membership and data by Private Market View
Candid Therapeutics valuation
Candid Therapeutics was valued at $657 million at its Series B in Aug 2024. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
Recent activity
In the last 90 days, Candid Therapeutics's record added 8 institutional fund marks (latest period Jul 2026).
How much has Candid Therapeutics raised?
Candid Therapeutics has raised $445 million across 1 recorded round since 2024. The largest was a $370 million Series B in Aug 2024.
Candid Therapeutics has filed 1 Form D with the SEC, most recently in Sep 2024 ($206 million sold to 33 investors).
Institutional holders and vehicles
3 SEC-registered funds reported 36 fair-value marks on Candid Therapeutics between Apr 2025 and Jul 2026, in their N-PORT filings. Filer-level marks and implied per-share values are available to Pro members.
Comparable companies
Comparable drug discovery names by valuation on PrivateMarketView: Abcuro ($700 million), Kardigan ($646 million) and VeraDermics (NYS: MANE) ($596 million).
How Candid Therapeutics's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For Candid Therapeutics, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by its last priced round. Question about this number? Full methodology →
Frequently asked about Candid Therapeutics
- What is Candid Therapeutics worth?
- Candid Therapeutics is valued at $657.0M as of Oct 2026. Valued at $657.0M at its Series B, Aug 2024. Nothing has traded since.
- How much has Candid Therapeutics raised?
- Candid Therapeutics has raised $445.0M in total funding across 1 recorded rounds.
- When did Candid Therapeutics last raise?
- Candid Therapeutics last raised in Aug 2024 (Early Stage VC (Series B)), raising $370.0M.